The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs
- PMID: 100122
- DOI: 10.1002/art.1780210714
The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs
Abstract
To detail the cost for one year of a chronic disease, 50 patients with Stage III rheumatoid arthritis were surveyed. Direct medical costs for this group were three times the national average, and 58% of these costs were covered by insurance. Indirect costs due to lost income were at least three times the direct medical costs, and transfer payments covered only 42% of these costs. Fifty-eight percent of the study group also sustained a major psychosocial loss. Uncovered income losses were the greatest economic burden for individuals with chronic rheumatoid arthritis. This striking ratio of indirect to direct medical costs has important implications for medical practice and health policy.
Similar articles
-
Morbidity impact of rheumatoid arthritis on society.Am J Med. 1985 Jan 21;78(1A):1-5. doi: 10.1016/0002-9343(85)90237-2. Am J Med. 1985. PMID: 3918440
-
Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.Int J Rheum Dis. 2018 Aug;21(8):1572-1580. doi: 10.1111/1756-185X.13028. Epub 2017 Feb 17. Int J Rheum Dis. 2018. PMID: 28211251
-
Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.Arthritis Rheum. 2003 Oct;48(10):2750-62. doi: 10.1002/art.11439. Arthritis Rheum. 2003. PMID: 14558079
-
The burden of rheumatoid arthritis: facts and figures.J Rheumatol Suppl. 1998 Jul;53:8-12. J Rheumatol Suppl. 1998. PMID: 9666412 Review.
-
The underestimated long term medical and economic consequences of rheumatoid arthritis.Drugs. 1995;50 Suppl 1:1-14. doi: 10.2165/00003495-199500501-00003. Drugs. 1995. PMID: 8714794 Review.
Cited by
-
Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece.Clinicoecon Outcomes Res. 2015 Jan 16;7:85-93. doi: 10.2147/CEOR.S75323. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 25653545 Free PMC article.
-
The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.Pharmacoeconomics. 1998 Sep;14(3):299-312. doi: 10.2165/00019053-199814030-00006. Pharmacoeconomics. 1998. PMID: 10186468
-
Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.Rheumatol Int. 2006 Jun;26(8):704-11. doi: 10.1007/s00296-005-0070-7. Epub 2005 Nov 1. Rheumatol Int. 2006. PMID: 16261384
-
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.Ann Rheum Dis. 2006 Sep;65(9):1175-83. doi: 10.1136/ard.2005.046367. Epub 2006 Mar 15. Ann Rheum Dis. 2006. PMID: 16540552 Free PMC article.
-
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.Ann Rheum Dis. 2002 May;61(5):429-37. doi: 10.1136/ard.61.5.429. Ann Rheum Dis. 2002. PMID: 11959767 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical